Breaking Finance News

A statement released earlier today by Vetr Inc. about Illumina, Inc. (NASDAQ:ILMN) bumps the target price to $197.84

Yesterday Illumina, Inc. (NASDAQ:ILMN) traded -0.01% lower at $177.38. The company’s 50-day moving average is $194.72 and its 200-day moving average is $179.64. The last stock close price is down 19.08% from the 200-day moving average, compared to the S&P 500 which has increased 0.04% over the same time. 292,831 shares of the stock were exchanged, down from an average trading volume of 951,219

Stating a potential upside of 0.12%, Vetr Inc. upped the price target of Illumina, Inc. (NASDAQ:ILMN) to $197.84

Previously on Monday June 12, 2017, Vetr Inc. reported about Illumina, Inc. (NASDAQ:ILMN) raised the target price from $0.00 to $197.84. At the time, this indicated a possible upside of 0.14%.

See Chart Below

Illumina, Inc. (NASDAQ:ILMN)

Illumina, Inc. has a 52 week low of $119.37 and a 52 week high of $214.21 with a P/E ratio of 42.92 The company’s market cap is currently $0.

In addition to Vetr Inc. reporting its target price, a total of 19 firms have reported on the stock. The consensus target price is $154.53 with 4 firms rating the stock a strong buy, 4 firms rating the stock a buy, 15 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Illumina, Inc. (NASDAQ:ILMN)

Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.